Literature DB >> 23455310

Hyperoxia, HMGB1, and ventilator-associated pneumonia: reducing risk by practicing what we teach.

Thomas P Kennedy, Steve Nelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23455310      PMCID： PMC3604084          DOI： 10.1165/rcmb.2013-0020ED

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN： 1044-1549            Impact factor:   6.914


× No keyword cloud information.
  22 in total

1.  Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro.

Authors:  Yan Ling; Zhi-Yong Yang; Tao Yin; Li Li; Wei-Wei Yuan; He-Shui Wu; Chun-You Wang
Journal:  Int Immunopharmacol       Date:  2010-11-21       Impact factor: 4.932

Review 2.  Bundles to prevent ventilator-associated pneumonia: how valuable are they?

Authors:  Charity Wip; Lena Napolitano
Journal:  Curr Opin Infect Dis       Date:  2009-04       Impact factor: 4.915

3.  Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.

Authors:  Narayanam V Rao; Brian Argyle; Xiaoyu Xu; Paul R Reynolds; Jeanine M Walenga; Margaret Prechel; Glenn D Prestwich; Robert B MacArthur; Bradford B Walters; John R Hoidal; Thomas P Kennedy
Journal:  Am J Physiol Cell Physiol       Date:  2010-04-07       Impact factor: 4.249

4.  Extracellular high mobility group box-1 (HMGB1) inhibits enterocyte migration via activation of Toll-like receptor-4 and increased cell-matrix adhesiveness.

Authors:  Shipan Dai; Chhinder Sodhi; Selma Cetin; Ward Richardson; Maria Branca; Matthew D Neal; Thomas Prindle; Congrong Ma; Richard A Shapiro; Bin Li; James H-C Wang; David J Hackam
Journal:  J Biol Chem       Date:  2009-12-11       Impact factor: 5.157

5.  Pulmonary levels of high-mobility group box 1 during mechanical ventilation and ventilator-associated pneumonia.

Authors:  Marieke A D van Zoelen; Akitoshi Ishizaka; Esther K Wolthuls; Goda Choi; Tom van der Poll; Marcus J Schultz
Journal:  Shock       Date:  2008-04       Impact factor: 3.454

6.  Antioxidants preserve macrophage phagocytosis of Pseudomonas aeruginosa during hyperoxia.

Authors:  Dympna M P Morrow; Tahereh Entezari-Zaher; John Romashko; Ali O Azghani; Mohammad Javdan; Luis Ulloa; Edmund J Miller; Lin L Mantell
Journal:  Free Radic Biol Med       Date:  2007-01-23       Impact factor: 7.376

7.  Hyperoxia exaggerates bacterial dissemination and lethality in Pseudomonas aeruginosa pneumonia.

Authors:  Yoshiaki Kikuchi; Kazuhiro Tateda; Etsu T Fuse; Tetsuya Matsumoto; Naomasa Gotoh; Jun Fukushima; Hajime Takizawa; Takahide Nagase; Theodore J Standiford; Keizo Yamaguchi
Journal:  Pulm Pharmacol Ther       Date:  2009-01-08       Impact factor: 3.410

8.  Clinicians' response to hyperoxia in ventilated patients in a Dutch ICU depends on the level of FiO2.

Authors:  Aafke Elizabeth de Graaff; Dave Anton Dongelmans; Jan Maria Binnekade; Evert de Jonge
Journal:  Intensive Care Med       Date:  2010-09-28       Impact factor: 17.440

9.  Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial.

Authors:  Barry Dixon; Marcus J Schultz; Roger Smith; James B Fink; John D Santamaria; Duncan J Campbell
Journal:  Crit Care       Date:  2010-10-11       Impact factor: 9.097

10.  Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients.

Authors:  Evert de Jonge; Linda Peelen; Peter J Keijzers; Hans Joore; Dylan de Lange; Peter H J van der Voort; Robert J Bosman; Ruud A L de Waal; Ronald Wesselink; Nicolette F de Keizer
Journal:  Crit Care       Date:  2008-12-10       Impact factor: 9.097
View more
  1 in total

1.  Glycyrrhizin Ameliorates Radiation Enteritis in Mice Accompanied by the Regulation of the HMGB1/TLR4 Pathway.

Authors:  Xiao-Min Zhang; Xiao Hu; Jin-Ying Ou; Shan-Shan Chen; Ling-Hui Nie; Lei Gao; Ling-Ling Zhu
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-31       Impact factor: 2.629
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.